Ibrutinib
4 brands · 3 companies · product forms
Opportunity snapshot
Who competes here
Top companies by brand count — concentrated market · leader share 50%
Price room
max/min price ratio 1.40x across 4 trusted points (Rs 177392.34-248207.37). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.
Brands & products on the market
Sample of 2 live products for Ibrutinib — each links to its own medicine page.
Why this score
Launch attractiveness
40% supply-gap(50) + 25% price-variation(10) + 20% low-competition(92) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.
Market saturation
3 canonical companies and 4 brands compete (saturation pegged at 30 companies / 150 brands).
Price room
max/min price ratio 1.40x across 4 trusted points (Rs 177392.34-248207.37). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.
Regulatory risk
No DRAP alerts on this molecule's brands.
Confidence
Full coverage.
Packaged brief for this moderate opportunity?
Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.
See packaged reports All 3868 molecules